Article | January 31, 2019

With Investors' Eyes On Biotechs, Biotechs Must Keep Their Eyes On Transparency

Source: TrialScope

By Darcy Grabenstein

dollar_money_pillls_finance_450x300

If recent pharmaceutical mergers and acquisitions are any indication, 2019 is poised to marked by industry deal-making. Earlier this month, the J.P. Morgan Healthcare Conference coincided with Eli Lilly & Co.’s $8 billion acquisition of Loxo Oncology Inc. The news came on the heels of the $74 billion merger of Bristol-Myers Squibb and Celgene, and the $5.1 billion acquisition of Tesaro Inc. by GlaxoSmithKline PLC.